Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Osteosarcoma × Doxorubicin × Clear all

Phase

Status

Completed 13 Terminated 4 Recruiting 4 Unknown 2 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 17 Breast Neoplasms 16 Lymphoma 11 Hodgkin Disease 10 Sarcoma 8 Neoplasms 8 Triple Negative Breast Neoplasms 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma, Follicular 7 Lymphoma, B-Cell 6 Burkitt Lymphoma 6 Ovarian Neoplasms 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Fallopian Tube Neoplasms 4 Sarcoma, Ewing 3 Recurrence 3 Endometrial Neoplasms 3 Carcinoma, Hepatocellular 3 Urinary Bladder Neoplasms 2 Sarcoma, Synovial 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Neurofibrosarcoma 2 Neuroblastoma 2 Lymphoma, Mantle-Cell 2 Lymphoma, AIDS-Related 2 Liposarcoma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

X-Rays 4 Phantoms, Imaging 4 Nuclear Medicine Department, Hospital 4 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 pembrolizumab 3 Specimen Handling 3 Biopsy 3 ulixertinib 2 tipifarnib 2 selpercatinib 2 regorafenib 2 olaparib 2 larotrectinib 2 ivosidenib 2 fludarabine 2 ensartinib 2 Etoposide 2 tocilizumab 1 tazemetostat 1 poly ICLC 1 palbociclib 1 naxitamab 1 mifamurtide 1 humanized 3F8 anti-GD2 monoclonal antibody 1 fludarabine phosphate 1 flt3 ligand protein 1 etoposide phosphate 1 erdafitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00470223 2025-06-08

OS2006

UNICANCER

Phase 3 Active not recruiting

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡